News & Events

News

Nexstim offers targeted and effective therapies and diagnostics for challenging brain diseases and disorders. Our technology is solidly grounded in scientific and clinical research. We closely collaborate with key opinion leaders who, like us, believe noninvasive brain stimulation harnesses the brain's own healing power—neuroplasticity. Nexstim is helping patients—and their families—get back the life they feared they had lost.

01-30-2017

Invitation to the Extraordinary General Meeting of Shareholders and cancellation of the invitation published on 25 January 2017

01-25-2017

Nexstim Plc: Invitation to the Extraordinary General Meeting of Shareholders, 25 January 2017

01-18-2017

Nexstim Plc issues shares in standby equity distribution agreement pursuant to the financing arrangement announced on 21 July 2016, 18 January 2017

01-16-2017

Increase of Nexstim Plc’s share capital with subscriptions based on stock options 2013A, 16 January 2017

01-12-2017

The conversion of the convertible loan between Nexstim Plc and Bracknor, 12 january 2017

01-11-2017

Nexstim Plc announces signing of an Independent Selling Representative Agreements in U.S.

01-09-2017

Conversion of the convertible bond entered into between Nexstim Plc and Bracknor to shares and issuance of shares pursuant to the financing arrangement announced on 21 July 2016, 9 January 2017

01-05-2017

Nexstim to present at Biotech Showcase 9th Annual Conference in San Francisco

12-22-2016

Nexstim Plc pre-close business update

12-21-2016

Conversion of the convertible bond entered into between Nexstim Plc and Bracknor to shares and issuance of shares pursuant to the financing arrangement announced on 21 July 2016, 21st December 2016

12-21-2016

Nexstim Plc receives FDA’s response to the proposed limited size stroke trial plan

12-21-2016

Conversion of the convertible bond entered into between Nexstim Plc and Bracknor to shares and issuance of shares pursuant to the financing arrangement announced on 21 July 2016, 21 December 2016